Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 293

Sort by

Sort Order Select

Journal Articles

Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature

Salma B. Abdelbaky, Brian Giacopelli, Kari G. Rabe, Kyoko Yamaguchi, Yue-Zhong Wu, Huihuang Yan, Tait D. Shanafelt, Sameer A. Parikh, Wei Ding, Paul J. Hampel, Sochilt Brown, James R. Cerhan, Celine M. Vachon, Neil E. Kay, Curtis A. Hanson, Alexander S. Parker, Esteban Braggio, Susan L. Slager, Christopher C. Oakes

Blood (2024) 143 (17): 1752–1757.

https://doi.org/10.1182/blood.2023022180

Published: 2024

Includes: Supplemental data

Journal Articles

CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS

Blood (2024) 143 (3): 258–271.

https://doi.org/10.1182/blood.2022018905

Published: 2024

Includes: Supplemental data

Journal Articles

Ibrutinib-based therapy reinvigorates CD8 + T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

Despoina Papazoglou, Xin Victoria Wang, Tait D. Shanafelt, Connie E. Lesnick, Nikolaos Ioannou, Giulia De Rossi, Sylvia Herter, Marina Bacac, Christian Klein, Martin S. Tallman, Neil E. Kay, Alan G. Ramsay

Blood (2024) 143 (1): 57–63.

https://doi.org/10.1182/blood.2023020554

Published: 2024

Includes: Supplemental data

Journal Articles

Incidence of Richter Transformation in Patients with Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL): A Cohort Study Evaluating Different Therapeutic Eras

Blood (2023) 142 (Supplement 1): 3271.

https://doi.org/10.1182/blood-2023-185076

Published: 2023

Journal Articles

Clinical Outcomes with Venetoclax-Based Treatment Regimens in Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2023) 142 (Supplement 1): 3276.

https://doi.org/10.1182/blood-2023-183007

Published: 2023

Journal Articles

Aberrant Heterochromatin Silences Immune Response Genes in Chronic Lymphocytic Leukemia

Zhiquan Wang, Olivia M. Depies, Sutapa Sinha, Weiguo Han, Sameer A. Parikh, Neil E. Kay

Blood (2023) 142 (Supplement 1): 3258.

https://doi.org/10.1182/blood-2023-182898

Published: 2023

Journal Articles

Outcomes of Patients with Small Lymphocytic Lymphoma (SLL) Receiving First Line Treatment

Blood (2023) 142 (Supplement 1): 3284.

https://doi.org/10.1182/blood-2023-181866

Published: 2023

Journal Articles

PD-1 Expression in Lymphoma Cells Mediates Cellular Proliferation By Engaging Phosphatase SHP-1/SHP-2

Blood (2023) 142 (Supplement 1): 3261.

https://doi.org/10.1182/blood-2023-177755

Published: 2023

Journal Articles

Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168

Blood (2023) 142 (Supplement 1): 416.

https://doi.org/10.1182/blood-2023-178259

Published: 2023

Journal Articles

Mosaic Chromosomal Alterations and Monoclonal B-Cell Lymphocytosis: Relationship and Risk of Hematologic Malignancies

Rosalie Griffin, Aswin Sekar, Sameer A. Parikh, Giulio Genovese, Dennis P. Robinson, Aaron D. Norman, Janet E. Olson, Kari G. Rabe, Nicholas J. Boddicker, Paul J. Hampel, Neil E. Kay, Timothy G. Call, James R. Cerhan, Esteban Braggio, Curtis A. Hanson, Caline M. Vachon, Tait D. Shanafelt, Benjamin L. Ebert, Susan L. Slager

Blood (2023) 142 (Supplement 1): 2690.

https://doi.org/10.1182/blood-2023-184696

Published: 2023

Journal Articles

An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients into Novel Categories with Different Risk of Early Treatment

Blood (2023) 142 (Supplement 1): 1892.

https://doi.org/10.1182/blood-2023-177884

Published: 2023

Journal Articles

Chronic Lymphoproliferative Disorder of Natural Killer Cells: Patient Characteristics, Laboratory Features, and Clinical Outcomes

Richard C. Godby, Kari G. Rabe, Steven R. Hwang, Hadiyah Audil, Susan L. Slager, Saad S. Kenderian, Neil E. Kay, Yucai Wang, Paul J Hampel, Sameer A. Parikh, Wei Ding, Min Shi

Blood (2023) 142 (Supplement 1): 4446.

https://doi.org/10.1182/blood-2023-182545

Published: 2023

Journal Articles

High Deletion Burden Identified By Whole Genome Sequencing Is Associated with Enhanced Risk in del17p CLL Patients

Preeti Trisal, Esteban Braggio, Nicholas Stong, Kay L. Medina, Sameer A. Parikh, Daniel L. Van Dyke, Kari G. Rabe, Zhiquan Wang, C. Chris Huang, Anita K. Gandhi, Neil E. Kay

Blood (2023) 142 (Supplement 1): 6509.

https://doi.org/10.1182/blood-2023-173881

Published: 2023

Journal Articles

Beyond CLL Progression: Unveiling Th17 and Th2 T Cell Subsets As Predictors of Pembrolizumab Response in Richter's Transformation

Prajish Iyer, Lu Yang, Sutapa Sinha, Miles Del Busso, Zhi-Zhang Yang, Hyojin Kim, Charla Secreto, Yucai Wang, Neil E. Kay, Stephen M Ansell, Wei Ding, Lili Wang

Blood (2023) 142 (Supplement 1): 1888.

https://doi.org/10.1182/blood-2023-181004

Published: 2023

Journal Articles

An Ex Vivo Monocyte Stimulation Test Predicts Severity of COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia (CLL)

Gordon Ruan, Xiaosheng Wu, Kimberly Gwin, Michelle K. Manske, Jithma P. Abeykoon, Taylor L. Witter, Matthew J. Schellenberg, Kari G Rabe, Sara J. Achenbach, Neil E. Kay, Sameer A. Parikh, Thomas E. Witzig

Blood (2022) 140 (Supplement 1): 8314–8315.

https://doi.org/10.1182/blood-2022-156815

Published: 2022

Journal Articles

Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome

Blood (2022) 140 (Supplement 1): 1530–1533.

https://doi.org/10.1182/blood-2022-160335

Published: 2022

Journal Articles

Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era

Sanjal H Desai, Raphael Mwangi, Yucai Wang, Umar Farooq, Eric Mou, Andrew L. Feldman, Sergei Syrbu, Susan L. Slager, Grzegorz S. Nowakowski, Matthew J. Maurer, Neil E. Kay, Thomas M. Habermann, Brian K. Link, Carrie A. Thompson, James R. Cerhan

Blood (2022) 140 (Supplement 1): 1934–1936.

https://doi.org/10.1182/blood-2022-165207

Published: 2022

Journal Articles

Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia with TP53 Mutations

Steven R Hwang, Yucai Wang, Kari G Rabe, Rong He, Saad S. Kenderian, Eli Muchtar, Paul J. Hampel, Neil E. Kay, Timothy G. Call, Amber Koehler, Amy L Behnken, Jose F. Leis, Esteban Braggio, Min Shi, David S. Viswanatha, Daniel L. Van Dyke, Susan L. Slager, Sameer A. Parikh, Wei Ding

Blood (2022) 140 (Supplement 1): 12390–12392.

https://doi.org/10.1182/blood-2022-165508

Published: 2022

Journal Articles

Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis

Blood (2022) 140 (Supplement 1): 9882–9884.

https://doi.org/10.1182/blood-2022-168152

Published: 2022

Journal Articles

Potential Drivers of Acquired Resistance to Idelalisib in CLL Patients

Saurabh Yadav, Jasneet Khalsa, Ishwarya Murali, Richard R. Furman, Neil E. Kay, Esteban Braggio, Jennifer R. Brown

Blood (2022) 140 (Supplement 1): 12373–12374.

https://doi.org/10.1182/blood-2022-166648

Published: 2022

NARROW

Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature

CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS

Ibrutinib-based therapy reinvigorates CD8 + T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

Incidence of Richter Transformation in Patients with Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL): A Cohort Study Evaluating Different Therapeutic Eras

Clinical Outcomes with Venetoclax-Based Treatment Regimens in Patients with Chronic Lymphocytic Leukemia (CLL)

Aberrant Heterochromatin Silences Immune Response Genes in Chronic Lymphocytic Leukemia

Outcomes of Patients with Small Lymphocytic Lymphoma (SLL) Receiving First Line Treatment

PD-1 Expression in Lymphoma Cells Mediates Cellular Proliferation By Engaging Phosphatase SHP-1/SHP-2

Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168

Mosaic Chromosomal Alterations and Monoclonal B-Cell Lymphocytosis: Relationship and Risk of Hematologic Malignancies

An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients into Novel Categories with Different Risk of Early Treatment

Chronic Lymphoproliferative Disorder of Natural Killer Cells: Patient Characteristics, Laboratory Features, and Clinical Outcomes

High Deletion Burden Identified By Whole Genome Sequencing Is Associated with Enhanced Risk in del17p CLL Patients

Beyond CLL Progression: Unveiling Th17 and Th2 T Cell Subsets As Predictors of Pembrolizumab Response in Richter's Transformation

An Ex Vivo Monocyte Stimulation Test Predicts Severity of COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia (CLL)

Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome

Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era

Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia with TP53 Mutations

Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis

Potential Drivers of Acquired Resistance to Idelalisib in CLL Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only